DEF: Orchestra BioMed Holdings Sets Date for 2025 Annual Stockholders Meeting

Orchestra BioMed Holdings will hold its 2025 Annual Meeting of Stockholders virtually on June 24, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Orchestra BioMed Holdings, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 24, 2025, at 1:00 p.m. Eastern Time.
• Stockholders of record as of April 28, 2025, are eligible to vote.
• The meeting will address the election of three Class II directors to serve until the 2028 annual meeting, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and any other business that may properly come before the meeting.
• The Board recommends voting FOR the election of Chris Cleary, Pamela Connealy, and David Pacitti as Class II directors, and FOR the ratification of Ernst & Young LLP's appointment.
• As of the record date, there were 38,312,512 shares of common stock outstanding.
• The company is providing proxy materials over the Internet to reduce environmental impact and costs.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment due to the routine nature of the information and the company's adherence to corporate governance best practices.

Positives

• The company is embracing virtual meeting technology to provide expanded access and cost savings for stockholders.
• The Board is composed of a majority of independent directors, ensuring strong corporate governance.
• The company has established Audit, Compensation, and Nominating and Corporate Governance Committees, each with written charters.
• The company has a written related person transaction policy to ensure fair dealings.
• The company provides a means for stockholders to communicate with the Board.
• The company has an anti-hedging and insider trading policy in place.

Risks

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.
• The company is dependent on Medtronic for the commercialization of AVIM-enabled pacing systems.

Future Outlook

The company is focused on advancing its AVIM therapy and Virtue Sirolimus AngioInfusion Balloon clinical programs, pursuing new acquisition/partnership opportunities, and executing as a public company.

Industry Context

The document reflects standard corporate governance practices for a publicly traded company, including the election of directors, appointment of auditors, and establishment of board committees.

Comparison to Industry Standards

• The board composition, with a majority of independent directors, aligns with Nasdaq requirements and general corporate governance best practices.
• The establishment of Audit, Compensation, and Nominating and Corporate Governance Committees is standard practice for publicly traded companies.
• The executive compensation structure, including base salary, bonus, and equity awards, is typical for companies of similar size and stage in the biotechnology and medical device industries.
• The company's related party transaction policy is consistent with SEC regulations and aims to ensure transparency and fairness in dealings with related parties.

Related Party Transactions

• Medtronic, which holds more than 5% of Orchestra's common stock, has an exclusive license and collaboration agreement with Orchestra for the development of AVIM therapy.
• During the years ended December 31, 2024 and 2023, the Company reimbursed Medtronic $4.3 million and $5.7 million, respectively, for development costs pursuant to the Medtronic Agreement.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions, including the election of directors and the ratification of the auditor.
• The company's corporate governance practices aim to protect the interests of all stakeholders.
• The company's focus on advancing its clinical programs could potentially benefit patients in the future.

Next Steps

• Stockholders are encouraged to vote their shares prior to the Annual Meeting.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Director Election, Auditor Ratification, Corporate Governance, Executive Compensation, Orchestra BioMed, Virtual Meeting